Immunomodulating effect of HCV during the development of chronic hepatitis C: toward new therapeutic approaches

Abstract : In France, HCV seroprevalence is estimated to be 1%. Most cases are related to illicit parenteral drug use. About 80% of patients infected by HCV will develop chronic infection with HCV RNA detectable in their serum. Factors involved in viral persistence are nor yet clearly identified. Patients who develop a chronic infection show a predominant Th2 response, but a weak Th1 response. This immune response imbalance could result from HCV interaction with dendritic cells functions. Several experimental and clinical studies support this hypothesis. New data on HCV strategy to establish chronic infection suggest that immmunomodulatory molecules could be useful to improve efficacy of therapy.
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-02014557
Contributor : Evelyne Schvoerer <>
Submitted on : Monday, February 11, 2019 - 4:17:32 PM
Last modification on : Thursday, March 7, 2019 - 1:01:58 AM

Identifiers

  • HAL Id : hal-02014557, version 1
  • PUBMED : 14978874

Collections

Citation

Françoise Stoll-Keller, Evelyne Schvoerer, Christine Thumann, Maria-Cristina Navas, Anne-Marie Aubertin. Immunomodulating effect of HCV during the development of chronic hepatitis C: toward new therapeutic approaches. Bulletin de l'Académie Nationale de Médecine, Elsevier Masson, 2003, 187 (6), pp.1147-60; discussion 1160-1. ⟨hal-02014557⟩

Share

Metrics

Record views

29